Review of bosentan in the management of pulmonary arterial hypertension
Eli Gabbay1, John Fraser2, Keith McNeil31Western Australian Lung Transplant Unit and Pulmonary Hypertension Service, Royal Perth Hospital, Western Australia, Australia; 2Critical Care Research Group, The Prince Charles Hospital, Rode Road, Chermside, Queensland, Australia; 3Transplant and Pulmonary...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2008-01-01
|
| Series: | Vascular Health and Risk Management |
| Online Access: | https://www.dovepress.com/review-of-bosentan-in-the-management-of-pulmonary-arterial-hypertensio-peer-reviewed-article-VHRM |
| _version_ | 1811280895984795648 |
|---|---|
| author | Eli Gabbay John Fraser Keith McNeil |
| author_facet | Eli Gabbay John Fraser Keith McNeil |
| author_sort | Eli Gabbay |
| collection | DOAJ |
| description | Eli Gabbay1, John Fraser2, Keith McNeil31Western Australian Lung Transplant Unit and Pulmonary Hypertension Service, Royal Perth Hospital, Western Australia, Australia; 2Critical Care Research Group, The Prince Charles Hospital, Rode Road, Chermside, Queensland, Australia; 3Transplant and Pulmonary Vascular Disease Unit, The Prince Charles Hospital, Rode Road, Chermside, Queensland, AustraliaAbstract: The dual endothelin receptor antagonist, bosentan, is an orally active therapy, which is effective in the treatment of pulmonary arterial hypertension (PAH). This review critically appraises the evidence for the efficacy of bosentan in idiopathic and familial PAH, in PAH associated with connective tissue disease and in PAH which may develop in association with other conditions. Data from the pivotal placebo controlled studies and their open labeled extensions as well as long term survival and quality of life data is presented. Data is also presented on the potential benefit of bosentan in patients with inoperable chronic thromboembolic pulmonary hypertension. The safety and tolerability of bosentan as well as drug interactions are discussed. Dosage recommendations in adults and pediatrics are presented. An algorithm is provided to guide the reader in monitoring potential increases in alanine and aspartate transaminase levels that may occur with bosentan use and the dose adjustments that are recommended as a result of any increase in the levels of these enzymes are shown. Finally, the role of bosentan as part of combination therapy in PAH is examined.Keywords: bosentan, pulmonary arterial hypertension, review |
| first_indexed | 2024-04-13T01:24:03Z |
| format | Article |
| id | doaj.art-206767ca47024b88b308781f13fda74a |
| institution | Directory Open Access Journal |
| issn | 1178-2048 |
| language | English |
| last_indexed | 2024-04-13T01:24:03Z |
| publishDate | 2008-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Vascular Health and Risk Management |
| spelling | doaj.art-206767ca47024b88b308781f13fda74a2022-12-22T03:08:41ZengDove Medical PressVascular Health and Risk Management1178-20482008-01-01Volume 38879002027Review of bosentan in the management of pulmonary arterial hypertensionEli GabbayJohn FraserKeith McNeilEli Gabbay1, John Fraser2, Keith McNeil31Western Australian Lung Transplant Unit and Pulmonary Hypertension Service, Royal Perth Hospital, Western Australia, Australia; 2Critical Care Research Group, The Prince Charles Hospital, Rode Road, Chermside, Queensland, Australia; 3Transplant and Pulmonary Vascular Disease Unit, The Prince Charles Hospital, Rode Road, Chermside, Queensland, AustraliaAbstract: The dual endothelin receptor antagonist, bosentan, is an orally active therapy, which is effective in the treatment of pulmonary arterial hypertension (PAH). This review critically appraises the evidence for the efficacy of bosentan in idiopathic and familial PAH, in PAH associated with connective tissue disease and in PAH which may develop in association with other conditions. Data from the pivotal placebo controlled studies and their open labeled extensions as well as long term survival and quality of life data is presented. Data is also presented on the potential benefit of bosentan in patients with inoperable chronic thromboembolic pulmonary hypertension. The safety and tolerability of bosentan as well as drug interactions are discussed. Dosage recommendations in adults and pediatrics are presented. An algorithm is provided to guide the reader in monitoring potential increases in alanine and aspartate transaminase levels that may occur with bosentan use and the dose adjustments that are recommended as a result of any increase in the levels of these enzymes are shown. Finally, the role of bosentan as part of combination therapy in PAH is examined.Keywords: bosentan, pulmonary arterial hypertension, reviewhttps://www.dovepress.com/review-of-bosentan-in-the-management-of-pulmonary-arterial-hypertensio-peer-reviewed-article-VHRM |
| spellingShingle | Eli Gabbay John Fraser Keith McNeil Review of bosentan in the management of pulmonary arterial hypertension Vascular Health and Risk Management |
| title | Review of bosentan in the management of pulmonary arterial hypertension |
| title_full | Review of bosentan in the management of pulmonary arterial hypertension |
| title_fullStr | Review of bosentan in the management of pulmonary arterial hypertension |
| title_full_unstemmed | Review of bosentan in the management of pulmonary arterial hypertension |
| title_short | Review of bosentan in the management of pulmonary arterial hypertension |
| title_sort | review of bosentan in the management of pulmonary arterial hypertension |
| url | https://www.dovepress.com/review-of-bosentan-in-the-management-of-pulmonary-arterial-hypertensio-peer-reviewed-article-VHRM |
| work_keys_str_mv | AT eligabbay reviewofbosentaninthemanagementofpulmonaryarterialhypertension AT johnfraser reviewofbosentaninthemanagementofpulmonaryarterialhypertension AT keithmcneil reviewofbosentaninthemanagementofpulmonaryarterialhypertension |